吸入用布地奈德混悬液在COPD中应用的有效性及安全性评价

Efficacy and safety evaluation of inhaled budesonide suspension in COPD

目的:探讨不同剂量布地奈德雾化吸入对慢性阻塞性肺疾病急性加重(AECOPD)治疗的有效性及安全性。方法:选取某医院2020年6月至2021年9月收治的AECOPD患者150例,随机分为高剂量组(50例),中剂量组50(例),低剂量组(50例),3组在常规治疗基础上,给予布地奈德混悬液雾化吸入治疗。高剂量组、中剂量组、低剂量组给药剂量分别为4.0、2.0、1.0mg/次,每日2次,比较3组患者的临床疗效、肺功能、血气分析改善情况、不良反应发生情况。结果:本研究中3组临床疗效比较无差异,3组患者治疗后肺功能指标与血气指标改善情况无统计学差异,住院时间高剂量组最短,存在统计学差异,3组患者不良反应发生率无统计学差异。结论:增加布地奈德雾化吸入剂量不提高临床疗效,但可减少患者住院时间,不增加不良反应发生率。

Objective:To explore the efficacy and safety of different doses of budesonide atomization inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods:150 patients with AECOPD treated in a hospital from June 2020 to September 2021 were treated with budesonide suspension atomization inhalation on the basis of routine treatment.The doses of high-dose group,medium-dose group and low-dose group were 4.0,2.0 and 1.0 mg/once,twice a day,respectively.The clinical efficacy,pulmonary function improvement of blood gas analysis and occurrence of adverse reactions.Results:There was no difference in clinical efficacy among the three groups.There was no significant difference in the improvement of pulmonary function and blood gas indexes among the three groups after treatment.The length of hospital stay in the high-dose group was the shortest,with statistical difference.There was no significant difference in the incidence of adverse reactions among the three groups.Conclusion:Increasing the dose of budesonide aerosol inhalation does not improve the clinical efficacy,but it can reduce the length of hospital stay and does not increase the incidence of adverse reactions.